MARKET

CLRB

CLRB

Cellectar Biosciences Inc
NASDAQ
2.540
0.000
0.00%
After Hours: 2.540 0 0.00% 19:30 08/27 EDT
OPEN
2.570
PREV CLOSE
2.540
HIGH
2.570
LOW
2.520
VOLUME
10.32K
TURNOVER
--
52 WEEK HIGH
6.52
52 WEEK LOW
2.200
MARKET CAP
24.01M
P/E (TTM)
-0.5529
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CLRB last week (0817-0821)?
Weekly Report · 3d ago
Cellectar Biosciences Earnings Call Highlights Clinical Momentum
TipRanks · 6d ago
Weekly Report: what happened at CLRB last week (0810-0814)?
Weekly Report · 08/17 10:16
Cellectar Biosciences reports Q2 EPS (57c), consensus (52c)
TipRanks · 08/17 08:00
Cellectar: Solid Cash Runway and De-Risking Clinical Milestones Support Buy Rating; $10 Price Target Reiterated
TipRanks · 08/14 16:55
Cellectar’s New Phase 3 WM Trial Puts Iopofosine I 131 on Investors’ Radar
TipRanks · 08/14 16:31
Cellectar Biosciences 13G Filing Shows Balyasny Asset Management Reports 9.99% Stake In Co As Of June 30, 2026, Holding 798,382 Shares And Warrants
Benzinga · 08/14 16:17
Cellectar Biosciences 13G Filing Shows StemPoint Capital Reports 9.99% Stake In Co As Of June 30, 2026, Holding 845,740 Shares Including Pre-Funded Warrants
Benzinga · 08/14 16:17
More
About CLRB
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.

Webull offers Cellectar Biosciences Inc stock information, including NASDAQ: CLRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLRB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLRB stock methods without spending real money on the virtual paper trading platform.